Senate committee advances the SAFE Drugs Act with interstate reporting and labeling duties for 503A compounders
S. 3794 cleared the Senate HELP Committee 17 to 5 on July 22, 2026. The reported bill keeps adverse event reporting, interstate volume reports and a not FDA approved label for 503A compounders, and drops the monthly cap on essentially a copy compounding.
The committee agreed to the SAFE Drugs Act of 2026, sponsored by Senators Banks and Heinrich, and Senator Cassidy reported it with an amendment on July 27 as Calendar No. 524. As reported it amends section 503A: compounders sending products out of state must forward serious adverse event reports to FDA, the home state and each receiving state, and anyone sending more than five percent of annual output out of state must report units by product type, by month and by state each January.
Every 503A product would carry a statement that it was compounded for an individual patient and has not been approved by FDA, plus MedWatch contacts. The committee struck the introduced bill's definitions, large scale outsourcing provisions, establishment fee and its limit of twenty essentially a copy compounds per month. The bill is not law and awaits floor action.
- 503A pharmacies shipping across state lines, especially above the five percent threshold.
- Nonresident and mail order compounders serving telehealth platforms nationally.
Not law. The bill has cleared committee and awaits Senate floor action; nothing changes until it passes both chambers and is signed.
| Source published | July 22, 2026 | Committee roll call vote, 17 to 5. |
|---|---|---|
| Effective | Not stated | If enacted, interstate volume reporting starts with the first calendar year after enactment. |
Interstate volume is what separates a community compounder from a national fulfilment operation, and today nothing reports it federally. A by state volume report is a record a receiving state can compare against its permit roll, so a pharmacy should already be able to say which states it ships to and whether it is licensed there.
- Work out what share of your compounded output left your state in the last year.
- Confirm you hold a nonresident permit in every state you ship to.
- Compare your labels with the proposed not FDA approved statement.
Licensure and Registration. The Licensure and Registration domain verifies state licensure, including nonresident permits, against the issuing boards. Interstate volume reporting would give regulators a second view of the same facts.
- HELP Committee executive session results, July 22, 2026 PrimaryU.S. Senate Committee on Health, Education, Labor, and PensionsRetrieved Sep 21, 2026
S. 3794, SAFE Drugs Act of 2026 (Agreed to by Roll Call Vote, 17-5).
- S. 3794, SAFE Drugs Act of 2026, reported in Senate with an amendment, Calendar No. 524 PrimaryU.S. Government Publishing OfficeS. 3794 (119th Congress), Reported in SenateRetrieved Sep 21, 2026
Sections 2 (reporting requirement) and 3 (labeling); struck text shown as deleted, including the twenty times in a single month limit.
- Senate HELP Committee advances Sen. Banks' SAFE Drugs Act SecondaryOffice of Senator Jim BanksRetrieved Sep 21, 2026
Know where your pharmacy stands before the rules change again.
Certified pharmacies are re-verified nightly against state boards, federal enforcement records and their own websites.